[-] Show simple item record

dc.contributor.authorDhir, Mashaaleng
dc.contributor.authorCrockett, David Geng
dc.contributor.authorStevens, Todd Meng
dc.contributor.authorSilberstein, Peter Teng
dc.contributor.authorHunter, William Jeng
dc.contributor.authorFoster, Jason Meng
dc.date.issued2014-08-06eng
dc.description.abstractAbstract Dermatofibrosarcoma Protuberans (DFSP) is a rare skin tumor, characterized by frequent local recurrence but is seldom metastatic. It is histologically characterized by storiform arrangement of spindle cells. Cytogenetically, most tumors are characterized by translocation 17:22 leading to overexpression of tyrosine kinase PDGFB which can be targeted with tyrosine kinase inhibitor, Imatinib. We describe the first case of unresectable pancreatic metastases from DFSP treated with neoadjuvant Imatinib and subsequently R0 metastectomy. Additionally, a comprehensive systematic review of DFSP pancreatic metastases and the current published data on the use of Imatinib in DFSP is summarized.eng
dc.description.versionPeer Reviewedeng
dc.identifier.citationClinical Sarcoma Research. 2014 Aug 06;4(1):8eng
dc.identifier.urihttp://dx.doi.org/10.1186/2045-3329-4-8eng
dc.identifier.urihttps://hdl.handle.net/10355/44873eng
dc.rights.holderMashaal Dhir et al.; licensee BioMed Central Ltd.eng
dc.titleNeoadjuvant treatment of Dermatofibrosarcoma Protuberans of pancreas with Imatinib: case report and systematic review of literatureeng
dc.typeJournal Articleeng


Files in this item

[XML]
[PDF]
[Excel]
[Excel]
[Excel]
[Excel]
[Excel]

This item appears in the following Collection(s)

[-] Show simple item record